These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 23984614

  • 1. The effect of intravitreal administration of bevacizumab on macular edema and visual acuity in age-related macular degeneration with subfoveolar choroidal neovascularisation.
    Ristić D, Vukosavljević M, Draganić B, Cerović V, Petrović N, Janićijević-Petrović M.
    Vojnosanit Pregl; 2013 Jul; 70(7):660-3. PubMed ID: 23984614
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy.
    Rush RB, Rush SW, Aragon AV, Ysasaga JE.
    Am J Ophthalmol; 2014 Aug; 158(2):337-44. PubMed ID: 24844972
    [Abstract] [Full Text] [Related]

  • 3. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group.
    Retina; 2008 Aug; 28(10):1387-94. PubMed ID: 18827735
    [Abstract] [Full Text] [Related]

  • 4. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 Aug; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF, Sánchez JG, Wu L, Berrocal MH, Alezzandrini AA, Restrepo N, Maia M, Farah ME, Brito M, Díaz-Llopis M, Rodríguez FJ, Reategui G, Iturralde-Iraola J, Udaondo-Mirete P, Pan-American Collaborative Retina Study Group.
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [Abstract] [Full Text] [Related]

  • 7. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment.
    Fong KC, Kirkpatrick N, Mohamed Q, Johnston RL.
    Clin Exp Ophthalmol; 2008 Nov; 36(8):748-55. PubMed ID: 19128380
    [Abstract] [Full Text] [Related]

  • 8. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS.
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [Abstract] [Full Text] [Related]

  • 9. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C, Boscia F, Recchimurzo N, Besozzi G, Cardascia N, Sborgia L, Niro A, Sborgia C.
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [Abstract] [Full Text] [Related]

  • 10. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C, Michels S, Prager F, Garhoefer G, Georgopoulos M, Polak K, Schmidt-Erfurth U.
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ.
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C.
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [Abstract] [Full Text] [Related]

  • 16. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.
    Lazic R, Gabric N.
    Graefes Arch Clin Exp Ophthalmol; 2007 Jan; 245(1):68-73. PubMed ID: 17111146
    [Abstract] [Full Text] [Related]

  • 17. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population.
    Azad RV, Khan MA, Chanana B, Azad S.
    Jpn J Ophthalmol; 2008 Jan; 52(1):52-6. PubMed ID: 18369701
    [Abstract] [Full Text] [Related]

  • 18. [Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD].
    Schaal KB, Engler C, Schütt F, Scheuerle A, Dithmar S.
    Ophthalmologe; 2008 Jun; 105(6):538-43. PubMed ID: 18299845
    [Abstract] [Full Text] [Related]

  • 19. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A, Stinnett S, Fekrat S.
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [Abstract] [Full Text] [Related]

  • 20. Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study.
    Saviano S, Leon PE, Mangogna A, Tognetto D.
    Digit J Ophthalmol; 2016 Jul; 22(2):46-53. PubMed ID: 27582675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.